Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Kane Biotech Inc KNBIF


Primary Symbol: V.KNE

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired... see more

TSXV:KNE - Post Discussion

Kane Biotech Inc > I wonder....
View:
Post by francoisl13 on Nov 05, 2024 1:33pm

I wonder....

...if KNE set the expectations to high (again) for Q4...here's what they are targeting for Q4/2024 (from their September presentation):
1. Financing announcement
2. Potential M&A announcement
3. Announce distribution agreements outside of North America - (done for some part of the world)
4.Obtain clearance from Health Canada on revyve Antimicrobial Wound Gel - (didn't see any official announcement)
5.Launch revyve Antimicrobial Wound Gel Spray
6.Commence DispersinB University of Miami Clinical Trial

It is Nov.5th...I wonder if any of the above will happen in Q4 considering that we're basically left with only 5-6 weeks before the Holidays and very little of the above have been confirmed and announced.

I understand that KNE is in a highly supervised and reglemented market but, setting up the expectations and then not meeting them is not doing any good to the company reputation especially with the investment community.

As I said many times, I like this company product lines and the way they are managing it but, not their 'bat average' in regards to meeting expectations they are setting up themself...

GLTA!
Comment by RoyMax123 on Nov 12, 2024 1:26pm
No 2 is done, so most likely No 1 will be announced shortly.
Comment by francoisl13 on Nov 12, 2024 1:51pm
Very good news.  We are expanding our product line, we are expanding our geographic footprint and all that at a, what seems, to be a decent cost. The most important part of it is that Dr. Francesco Bellini is behind FB Dermatology, he is a 'legend' ! I hope they will find him a spot on our board...if he wants to join it would be a major acquisition for KNE. GLTA!
Comment by KevinOleary on Nov 12, 2024 2:41pm
The expectations that you don't like are really the estimates of how long it will take for the FDA to get it's act together and allow the acne and dispersin trials to start. kne does not control the FDA in any way, so it's a wait and see game to see what new ideas the eggheads at the FDA come up with to roadblock the start.
Comment by francoisl13 on Nov 12, 2024 5:15pm
Yo kevinOleary, long time no talk... Yup agree... but understanding the fact that we don't have control over the FDA agenda should give KNE management another reason to set the expectations a little differently, they seem to always be overly optimistic...I'd rather see them a little more pessimistic and then meet the expectations that they are setting themself... I don't know if they ...more  
Comment by KevinOleary on Nov 12, 2024 5:31pm
I don't think I was clear enough. Only a mind reader can know what the FDA will do, and you would have to read a bunch of minds because it is very bureaucratic and needs a bunch of people to check off their secret internal boxes before you can move forward. The FDA isn't some user friendly place with a nice little help desk for people who aren't getting any info. They schedule meetings ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities